中固醫療與廣州金沙洲醫院簽訂合作協議 攜手推動深合區醫療健康產業發展 China Solid Medical & GZ Jinshazhou Hospital Tie-Up for Hengqin Healthcare
【即時新聞】中固醫療投資集團與廣州中醫藥大學金沙洲醫院簽訂合作協議，雙方將攜手共建獨具特色、更契合患者需求的腫瘤學科體系，引入前沿的研究成果與先進治療理念，進一步提升橫琴中固腫瘤醫院的核心競爭力，為橫琴粵澳深度合作區的建設貢獻重要力量。
中固醫療投資集團是中國最早投資質子重離子腫瘤治療系統、生物科技和高端醫療服務的企業之一。2023年7月，中固旗下複美國際和澳門大學簽署合作協議，成立了澳大珠研院-複美長青聯合實驗室，主要是研究肝細胞類器官和生物免疫治療的相關臨床研究和應用。目前，中固旗下位於橫琴粵澳中醫院產業園內的複美國際精准醫療中心已經開始運營，質子重離子醫院項目已經開始進入設計等施工前的準備，預計今年5月正式開工建設。醫院總投資26億元，主要是以質子重離子治療為主，生物免疫治療為輔的高端腫瘤專科醫院。
隨著橫琴中固腫瘤醫院項目的持續推進，醫院將為深合區內及更廣泛區域的患者提供優質的腫瘤醫療服務，吸引更多醫療資源在此彙聚，進一步推動深合區醫療健康產業的繁榮發展，深化粵澳在醫療領域的深度融合與協同發展。
中固醫療投資集團董事長張浩表示，此次合作意義重大，集團將與金沙洲醫院緊密攜手，全力以赴推進橫琴中固腫瘤醫院的發展，使其成為橫琴粵澳深度合作區一張亮眼的醫療名片。
金沙洲醫院院長劉文勝強調，會積極履行合作義務，充分發揮優勢，助力實現共同目標。
【Breaking News】 China Solid Medical Investment Group and Guangzhou University of Chinese Medicine Jinshazhou Hospital have signed a cooperation agreement. The two parties will collaborate to build a distinctive oncology discipline system that better meets patient needs, introducing cutting-edge research achievements and advanced treatment concepts. This initiative aims to further enhance the core competitiveness of Hengqin China Solid Tumor Hospital and contribute significantly to the development of the Hengqin-Guangdong-Macao Deep Cooperation Zone.
China Solid Medical Investment Group is one of the earliest enterprises in China to invest in proton/heavy-ion tumor therapy systems, biotechnology, and high-end medical services. In July 2023, Freelymedical International, under China Solid, signed a cooperation agreement with the University of Macau, establishing the UM Zhuhai Academy - Freelymedical Evergreen Joint Laboratory. This lab primarily focuses on clinical research and application related to hepatocyte organoids and bioimmunotherapy. Currently, the Freelymedical International Precision Medical Center, located within the Hengqin-Guangdong-Macao Traditional Chinese Medicine Industrial Park and under China Solid, has commenced operations. The proton/heavy-ion hospital project has entered the pre-construction design and preparation phase and is expected to officially commence construction in May this year. With a total investment of 2.6 billion RMB, the hospital will be a high-end specialized oncology facility primarily utilizing proton and heavy-ion therapy, supplemented by bioimmunotherapy.
With the continuous advancement of the Hengqin China Solid Tumor Hospital project, the hospital will provide high-quality oncology medical services to patients within the Deep Cooperation Zone and broader regions. It aims to attract more medical resources to gather here, further promoting the prosperous development of the healthcare industry in the Deep Cooperation Zone and deepening the integration and collaborative development between Guangdong and Macao in the medical field.
Mr. Zhang Hao, Chairman of China Solid Medical Investment Group, stated that this cooperation is of great significance. The Group will work closely with Jinshazhou Hospital and go all out to advance the development of Hengqin China Solid Tumor Hospital, making it a standout medical landmark within the Hengqin-Guangdong-Macao Deep Cooperation Zone.
President Liu Wensheng of Jinshazhou Hospital emphasized that the hospital will actively fulfill its cooperative obligations, fully leverage its advantages, and contribute to achieving the common goals.
Looking ahead, propelled by the joint efforts of China Solid Medical Investment Group and Jinshazhou Hospital, Hengqin China Solid Tumor Hospital is poised to embrace a new phase of development. It will inject robust momentum into the high-quality development of the Hengqin-Guangdong-Macao Deep Cooperation Zone, writing a remarkable chapter in regional development empowered by medical collaboration.
